Anatara Lifesciences Ltd has released a press release.
Appendix 4C & Q1 FY25 Activities Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Anatara Lifesciences Ltd on 6ix
Story so far
Earlier from Anatara Lifesciences
- GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update
- Anatara's GaRP granted EU patent
- GaRP Irritable Bowel Syndrome Clinical Trial Update
- $626,000 received in R&D Tax Incentive for FY24
- Appendix 4E & Financial Report 30 June 2024
Later from Anatara Lifesciences
- Chair's Address to Shareholders
- Successful Placement of $660k and Share Purchase Plan
- Share Purchase Plan Offer Booklet
- GaRP-IBS Clinical Trial Update
- Australian Patent Granted for GaRP Product
Follow Anatara Lifesciences into a list and get an email when it puts out news.
Follow Anatara Lifesciences